From the Guidelines
Jardiance (empagliflozin) should be used at a dose of 10 mg daily for patients with an eGFR of 30-44 mL/min/1.73 m2, and its use is not recommended with an eGFR of less than 45 mL/min/1.73 m2 for glycemic control or less than 20 mL/min/1.73 m2 for heart failure 1.
Key Considerations
- The dosage of Jardiance may need to be adjusted based on the patient's kidney function, as indicated by their eGFR.
- For patients with an eGFR of 30-44 mL/min/1.73 m2, the recommended dose is 10 mg daily 1.
- Jardiance is not recommended for patients with severe kidney disease (eGFR less than 45 mL/min/1.73 m2) or end-stage renal disease 1.
Potential Side Effects
- Common side effects of Jardiance include urinary tract infections and genital yeast infections due to the increased glucose in urine.
- Patients should monitor for signs of diabetic ketoacidosis, which is a rare but serious side effect.
Patient Management
- Patients should stay well-hydrated while taking Jardiance to reduce the risk of dehydration and maintain kidney function.
- Patients should continue their prescribed diet and exercise program while taking this medication.
Important Notes
- Glucose-lowering efficacy is reduced with SGLT2 inhibitors as eGFR declines, but kidney and cardiovascular benefits are preserved 1.
- Dulaglutide, liraglutide, and injectable semaglutide have demonstrated evidence of cardiovascular benefit in large CV outcome trials 1.
From the FDA Drug Label
The recommended dose of JARDIANCE is 10 mg once daily in the morning, taken with or without food. In patients tolerating JARDIANCE, the dose may be increased to 25 mg [see Clinical Studies (14)]. JARDIANCE should not be initiated in patients with an eGFR less than 45 mL/min/1.73 m2. No dose adjustment is needed in patients with an eGFR greater than or equal to 45 mL/min/1.73 m2.
The recommended dosage of Jardiance is:
- 10 mg once daily in the morning, taken with or without food
- May be increased to 25 mg in patients tolerating the medication Key considerations:
- Patients with renal impairment (eGFR less than 45 mL/min/1.73 m2) should not initiate Jardiance
- No dose adjustment is needed in patients with an eGFR greater than or equal to 45 mL/min/1.73 m2 2 2
From the Research
Jardiance Dosage Information
- The provided studies do not directly mention the dosage of Jardiance (empagliflozin) in relation to the question.
- However, the studies do mention the dosage of empagliflozin used in the trials:
- In the EMPA-KIDNEY trial 3, patients received empagliflozin 10 mg once daily.
- In the post-trial follow-up of the EMPA-KIDNEY trial 4, patients had previously received empagliflozin 10 mg once daily during the active trial period.
- In the study comparing empagliflozin to gliclazide 5, patients received empagliflozin 10 mg QD (once daily).
- It is essential to consult the prescribing information or a healthcare professional for the recommended dosage of Jardiance, as the dosage may vary depending on the specific condition being treated and individual patient factors.
Empagliflozin Dosage in Clinical Trials
- The dosage of empagliflozin used in clinical trials was typically 10 mg once daily 3, 4, 5.
- In one study, patients received empagliflozin 10 mg or 25 mg 6, but the 25 mg dosage is not commonly mentioned in the other studies.
Kidney Function and Empagliflozin
- Empagliflozin has been shown to have beneficial effects on kidney function in patients with chronic kidney disease 3, 4.
- The studies suggest that empagliflozin can reduce the risk of kidney disease progression or death from cardiovascular causes in patients with chronic kidney disease 3, 4.
- However, the dosage of empagliflozin used in these studies was typically 10 mg once daily, and it is unclear if different dosages would have the same effects.